Related Experiment Video
Updated: Jan 17, 2026
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis
Vanessa Pietrowski Baldin1, Christopher L Harding1, Diana Quach2
1Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Abstract:
The identification of novel agents with mechanisms of action distinct from those currently utilized in tuberculosis treatment remains a significant challenge. The mycobacterial protein MmpL3 has emerged as a promising drug target due to its essential role in the synthesis of the cell wall of Mycobacterium tuberculosis. We previously identified novel thienopyrimidine amides(TPAs) with good anti-tubercular activity. We profiled a subset of TPAs, determining activity against intracellular bacteria and bactericidal activity against replicating bacteria. We ran assays to determine the mode of action by measuring cell wall stress, ATP production, and bacterial cytological profiling. We determined activity against a strain of M. tuberculosis with mutations in MmpL3. We isolated and sequenced resistant mutants. We tested five analogs against a strain of M. tuberculosis with mutations in MmpL3 and determined that they lost potency. Analogs induced PiniBAC, a reporter for cell wall stress, and led to an ATP boost characteristic of cell wall inhibitors. Bacterial cytological profiling of a representative compound revealed a morphological profile consistent with other MmpL3 inhibitors. Together, our data support MmpL3 as the most probable drug target for the TPA analogs and add to the growing list of scaffolds that can inhibit this vulnerable transporter.
Insights
Novel thienopyrimidine amides show promise as tuberculosis treatments by targeting the essential MmpL3 protein. These compounds disrupt cell wall synthesis, offering a new approach against drug-resistant Mycobacterium tuberculosis.
Area of Science:
- Microbiology
- Medicinal Chemistry
- Drug Discovery
Background:
- Tuberculosis (TB) treatment faces challenges due to the need for novel agents with distinct mechanisms of action.
- The mycobacterial protein MmpL3 is crucial for Mycobacterium tuberculosis cell wall synthesis and represents a promising drug target.
- Previous research identified thienopyrimidine amides (TPAs) with significant anti-tubercular activity.
Purpose of the Study:
- To investigate the mechanism of action of novel thienopyrimidine amides (TPAs).
- To confirm MmpL3 as the drug target for TPAs.
- To evaluate the anti-tubercular activity and resistance profiles of TPAs.
Main Methods:
- Assays measuring cell wall stress (PiniBAC induction) and ATP production.
- Bactericidal activity testing against replicating M. tuberculosis.
- Resistance studies involving mutant strain analysis and sequencing.
- Bacterial cytological profiling to assess morphological changes.
Main Results:
- TPAs demonstrated activity against intracellular and replicating bacteria.
- Resistance studies confirmed MmpL3 as the target, as analogs lost potency against MmpL3-mutated strains.
- TPAs induced cell wall stress and increased ATP production, characteristic of MmpL3 inhibitors.
- Bacterial cytological profiling supported MmpL3 inhibition.
Conclusions:
- The thienopyrimidine amide (TPA) analogs most likely target the MmpL3 transporter.
- These findings contribute to the development of new anti-tubercular scaffolds targeting MmpL3.
- TPAs represent a promising class of compounds for novel tuberculosis therapies.
